| Literature DB >> 28350317 |
Raffaele Conte1, Valentina Marturano2,3, Gianfranco Peluso4, Anna Calarco5, Pierfrancesco Cerruti6.
Abstract
Phytocompounds have been used in medicine for decades owing to their potential in anti-inflammatory applications. However, major difficulties in achieving sustained delivery of phyto-based drugs are related to their low solubility and cell penetration, and high instability. To overcome these disadvantages, nanosized delivery technologies are currently in use for sustained and enhanced delivery of phyto-derived bioactive compounds in the pharmaceutical sector. This review focuses on the recent advances in nanocarrier-mediated drug delivery of bioactive molecules of plant origin in the field of anti-inflammatory research. In particular, special attention is paid to the relationship between structure and properties of the nanocarrier and phytodrug release behavior.Entities:
Keywords: cannabinoids; carbohydrates; essential oils; inflammation; nanocapsules; nanoparticles; nanosized delivery systems; phytochemicals; polyphenols; terpenoids
Mesh:
Substances:
Year: 2017 PMID: 28350317 PMCID: PMC5412295 DOI: 10.3390/ijms18040709
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of the main characteristics of: acute (A) and chronic (B) inflammation.
Figure 2Examples of organic material-based nanosized drug delivery systems.
Figure 3Nanoparticle-mediated delivery of different classes of anti-inflammatory natural compounds.
Figure 4Topical application of nanoencapsulated curcumin slowed the progression of osteoarthritis induced by destabilization of the medial meniscus (DMM) in mice. Mice with DMM were treated daily with topical application of curcumin nanoparticles or vehicle. Mice treated topically with curcumin nanoparticles (Nano-C) exhibited improved Safranin O staining (A); lower Osteoarthritis Research Society International (OARSI) scores (B); and reduced synovitis (C); and subchondral bone plate thickness (D) at eight weeks after surgery compared to that in vehicle control (Veh) (* p < 0.05, t-test, n = 5/group). Reproduced from [96] (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891896).
Nanosized delivery systems for anti-inflammatory polyphenols.
| Bioactive Principle | Nanovector | Type of Delivery System | Experimental Model | Reference |
|---|---|---|---|---|
| Quercetin | Nanoparticles | NP of soya lecithin, Tween-80 and PEG | In vivo (rats) | [ |
| PLGA NP containing quercetin | In vitro | [ | ||
| Eudragit-polyvinyl alcohol quercetin-loaded NP | In vitro | [ | ||
| Quercetin-PLGA NP | In vivo (rats) | [ | ||
| Nanocapsules | Lipid-coated NC | In vitro | [ | |
| Quercetin-PLGA NC | ||||
| Resveratrol | Nanoparticles | PLGA NP containing resveratrol | In vivo (Wistar male rats) | [ |
| Eudragit RL 100 NP | In vitro/In vivo | [ | ||
| Carboxymethyl chitosan NP | In vitro/In vivo (rats) | [ | ||
| Solid lipid nanoparticles | SLN with a controlled release profile | In vitro | [ | |
| Resveratrol loaded SLN | In vivo (Wistar male rats) | [ | ||
| Cyclodextrins | CD-based nanosponges | In vitro | [ | |
| Ellagic acid | Nanoparticles | Ellagic acid-loaded PLGA NP | In vitro | [ |
| PLGA-PCL ellagic acid NP | In vivo (rats with induced nephrotoxicity) | [ | ||
| Curcumin | Nanoparticles | Hydrogel/glass | In vivo (rats with post-traumatic osteoarthritis) | [ |
| Nanoemulsions | o/w nanoemulsion containing curcumin in the oil phase | In vitro | [ | |
| Lipid nanoparticles | Lecithin liposomes | In vivo (rats) | [ |
NP, nanoparticles; PEG, polyethylene glycol; PLGA, polylactic-co-glycolic acid; NC, nanocapsules; SLN, solid lipid nanoparticles; CD, cyclodextrins; PCL, polycaprolactone; o/w, oil in water.
Nanosized delivery systems for anti-inflammatory phytocannabinoids.
| Bioactive Principle | Nanovector | Type of Delivery System | Experimental Model | Reference |
|---|---|---|---|---|
| Δ-9-Tetrahydrocannabinol | Lipid nanoparticles | Nanostructured lipid carriers | In vitro | [ |
| Nanoparticles | Lipid NP containing lecithin | In vitro | [ | |
| PLGA NP | In vitro/In vivo | [ | ||
| Cannabidiol loaded PCL NP | In vitro | [ | ||
| Δ9-THC-loaded PLGA NP | In vivo (immunocompetent C57BL/6 mice) | [ |
Nanosized delivery systems for anti-inflammatory phytosterols.
| Bioactive Principle | Nanovector | Type of Delivery System | Experimental Model | Reference |
|---|---|---|---|---|
| Phytosterol | Nanodispersion | Nanodispersion produced by emulsification-evaporation | In vitro | [ |
| Colloidal particles using antisolvent precipitation | In vitro | [ | ||
| Suspensions of submicron particles of phytosterol | In vitro | [ |
Nano sized delivery systems for anti-inflammatory carbohydrates.
| Bioactive Principle | Nanovector | Type of Delivery System | Experimental Model | Reference |
|---|---|---|---|---|
| Mannose-6-phosphate | Liposomes | Liposomes containing | In vitro | [ |
| Liposomes containing | In vitro | [ | ||
| Nanocapsules | Polyamide NC | In vitro | [ |
Nanosized delivery systems for anti-inflammatory essential oils.
| Bioactive Principle | Nanovector | Type of Delivery System | Experimental Model | Reference | |
|---|---|---|---|---|---|
| Oregano and Cassia EO | Nanoparticles | Corn zein NP | In vitro | [ | |
| Thymol and carvacrol | Nanoparticles | Corn zein NP | In vitro | [ | |
| Cinnamon and thyme EO | Cyclodextrins | Inclusion in CD | In vitro | [ | |
| Nanoparticles | Alginate/cashew gum NP | In vitro | [ | ||
| Cumin and basil EO | Nanocapsules | Polyamide NC | In vitro | [ | |
Nanosized delivery systems for anti-inflammatory terpenoids.
| Bioactive Principle | Nanovector | Type of Delivery Systems | Experimental Model | Reference |
|---|---|---|---|---|
| Squalene | Nanocapsules | Polyelectrolyte multilayer NC | In vitro | [ |
| Lycopene | Nanoemulsions | Aqueous propolis and lycopene | In vivo (albino guinea pigs) | [ |
| Nanoparticles | SLN | In vitro | [ | |
| Cyclodextrins | Inclusion in CD | In vitro | [ | |
| Cyclodextrins | Inclusion in CD | In vitro | [ | |
| (−)-Linalool | Cyclodextrins | Inclusion in CD | In vivo (rodents) | [ |
| Carvacrol | Cyclodextrins | Inclusion in CD | In vivo (rodents with induced tumors) | [ |
Figure 5Schematic diagram of the phytocompounds effects on the main cellular pathways involved in inflammation. After cell internalization of a nanovector, encapsulated phytocompounds are released into cytoplasm. Their anti-inflammatory action is elicited via inhibition of nitric oxide (NO) production by nitric oxide synthase (iNOS); reduction of arachidonic acid metabolites and prostaglandins through inhibition of the cyclooxygenase (COX) and Phospholipase A2 (PLA2) pathways; and regulation of nuclear factor NF-κB and mitogen-activated protein kinases (MAPKs) pathways, which modulate the expression of pro- and anti-inflammatory mediators including cytokines, chemokines, and adhesion molecules.